<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="t0005">
 <label>Table 1</label>
 <caption>
  <p>Candidate COVID-19 vaccines currently in phase 1 or 2 human clinical trials.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Platform</th>
    <th>Description</th>
    <th>Advantages</th>
    <th>Disadvantages</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>
     <bold>Recombinant Viral vector</bold>
    </td>
    <td>Unrelated virus engineered to encode the target gene of the pathogen. Viral vectors can be replicating or non-replicating</td>
    <td>Induces high cellular and humoral immune responses</td>
    <td>Possible pre-existing immunity against vectorRisk of reversion to virulenceLimitations in scaling-up production</td>
   </tr>
   <tr>
    <td>
     <italic>Candidate vaccines:</italic>
    </td>
    <td colspan="3">
     <bold>Ad5-CoV</bold>Adenovirus Type 5 vector; antigen: Spike proteinPhase I: CanSino Biologics ChiCTR2000030906 
     <xref rid="b0440" ref-type="bibr">[88]</xref>/NCT04313127 
     <xref rid="b0445" ref-type="bibr">[89]</xref>Phase II: Institute of Biotechnology; Academy of Military Medical SciencesChiCTR2000031781 
     <xref rid="b0450" ref-type="bibr">[90]</xref>/NCT04341389 
     <xref rid="b0455" ref-type="bibr">[91]</xref>Participants: 18–60 years; Phase I n=108Phase II: n=508
     <italic>Phase I: vaccine was safe and tolerable. No serious adverse effects. 63 participants (Low dose n=18 [50%); moderate dose n=18 [50%]; high dose n=27 [75%]) developed four fold rise in neutralising antibody titres by Day 28. Pre-existing immunity to Ad5 neutralising antibody titre was observed in half of the participants before vaccination. Out of these, a low proportion seroconverted</italic>
     <xref rid="b0380" ref-type="bibr">[76]</xref>, 
     <xref rid="b0005" ref-type="bibr">[1]</xref>
     <bold>AZD1222 (previous known as ChAdOx1 nCoV-19)</bold>Simian adenoviral vaccine vector; antigen: Spike proteinPhase I/II: University of Oxford NCT04324606 
     <xref rid="b0460" ref-type="bibr">[92]</xref>Participants: 18-55 years; n= 1090
    </td>
   </tr>
   <tr>
    <td>
     <bold>Inactivated</bold>
    </td>
    <td>Pathogen virus inactivated by chemicals or radiation</td>
    <td>Easy to prepareHigh safety</td>
    <td>Variable efficacy</td>
   </tr>
   <tr>
    <td>
     <italic>Candidate vaccines:</italic>
    </td>
    <td colspan="3">
     <bold>PiCoVacc</bold>Phase I/II: Sinovac Biotech Co NCT04352608 
     <xref rid="b0465" ref-type="bibr">[93]</xref>Participants: 18-59 years; Phase I n=144; Phase II n=600Phase I/II: Sinovac Biotech Co NCT04383574 
     <xref rid="b0470" ref-type="bibr">[94]</xref>Participants: ≥60 years; Phase I n=72; Phase II n=350
     <bold>Inactivated novel coronavirus vaccine</bold>Phase I/II: Beijing Institute of Biological Products/SinopharmChiCTR2000032459 
     <xref rid="b0475" ref-type="bibr">[95]</xref>Recruitment: Age &gt;/= 3 years; Phase I n=480; Phase II n=1168
     <bold>Inactivated novel coronavirus vaccine</bold> Phase I/II: Wuhan Institute of Biological Products/SinopharmChiCTR2000031809 
     <xref rid="b0475" ref-type="bibr">[95]</xref>Participants: Age &gt;/= 6 years; Phase I n=288; Phase II n=1168
    </td>
   </tr>
   <tr>
    <td>
     <bold>Live attenuated</bold>
    </td>
    <td>Live virus whose genome(s) is mutated, inducing immune response but not disease</td>
    <td>Induces long-term immunity</td>
    <td>Expensive to produce</td>
   </tr>
   <tr>
    <td>
     <italic>Candidate vaccines:</italic>
    </td>
    <td colspan="3">Nil in clinical trials as yet</td>
   </tr>
   <tr>
    <td>
     <bold>Protein subunit</bold>
    </td>
    <td>Components of target antigen protein produced in laboratory; some vaccines may use nanoparticle technology</td>
    <td>High safetyScalability</td>
    <td>High costLower immunogenicity and may require adjuvant or repeat doses</td>
   </tr>
   <tr>
    <td>
     <italic>Candidate vaccines:</italic>
    </td>
    <td colspan="3">
     <bold>NVX-CoV2373</bold>Phase I: Novovax NCT04368988 
     <xref rid="b0480" ref-type="bibr">[96]</xref>Participants: 18-59 years; n=131
    </td>
   </tr>
   <tr>
    <td>
     <bold>Virus like particle</bold>
    </td>
    <td>Non-infectious self- assembling viral structural proteins</td>
    <td>Induces strong immune response</td>
    <td>Limitations in manufacturing production</td>
   </tr>
   <tr>
    <td>
     <italic>Candidate vaccines:</italic>
    </td>
    <td colspan="3">Nil in clinical trial as yet</td>
   </tr>
   <tr>
    <td>
     <bold>mRNA</bold>
    </td>
    <td>mRNA encoding target antigen (may be complexed with lipid- or polymer-based nanoparticles)</td>
    <td>Easier to designInduces strong immune responseRapid manufacture</td>
    <td>Requires mRNA to be encapsulated otherwise unstable under physiological conditions</td>
   </tr>
   <tr>
    <td>
     <italic>Candidate vaccines:</italic>
    </td>
    <td colspan="3">
     <bold>BNT162</bold>Phase I/II: BioNTech/PfizerFour candidates, two candidates include a nucleoside modified mRNA, one a uridine containing mRNA and the fourth self- amplifying mRNA. Each combined with a lipid nanoparticle formulation.Germany 2020-001038-36 
     <xref rid="b0485" ref-type="bibr">[97]</xref>Participants: 18–55 years; n=196USA NCT04368728 
     <xref rid="b0480" ref-type="bibr">[96]</xref>Participants: 18–85 years; n=7600
     <bold>mRNA-1273Lipid nano-particle (LNP)-encapsulated mRNA vaccine;Coding antigen: full length S-protein</bold>Phase I/II: Moderna/National Institute of Allergy and infectious diseasesNCT04283461 
     <xref rid="b0295" ref-type="bibr">[59]</xref>Participants: 18-55 years, extended to 99 years n=155
     <italic>Interim Phase 1 Data: 15 participants seroconverted by day 15; 8 participants: all developed neutralizing antibodies</italic>
     <xref rid="b0385" ref-type="bibr">[77]</xref>
    </td>
   </tr>
   <tr>
    <td>
     <bold>DNA</bold>
    </td>
    <td>DNA that encodes the target antigen</td>
    <td>Easier to designRapid manufacture</td>
    <td>May require a special approach to administer the vaccine (e.g. electroporation device)May requires adjuvant Uncertainty of safety issues</td>
   </tr>
   <tr>
    <td/>
    <td colspan="3">
     <bold>INO-4800</bold>Phase I: Inovio Pharmaceuticals NCT04336410 
     <xref rid="b0490" ref-type="bibr">[98]</xref>Participants : 18-50 years n=40
     <bold>Plasmid DNA oral vaccine (bacTRL-IL-Spike-1)</bold>Phase 1: Symvivo NCT04334980 
     <xref rid="b0495" ref-type="bibr">[99]</xref>Participants: 19=55 years; n= 84
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
